SLC31A1 and cancer: Although the potential role of copper chelator tetrathiomolybdate (TTM) in cancer therapy has been explored,[19, 20] primarily benefiting patients with CTR1 amplification,[16, 21, 22, 23, 24] the stratification of patients for copper chelator therapy warrants further exploration, given the low rate of CTR1 alterations.